.ai-based software may help predict risk of dementia
.treatment delays are also causing needless anxiety and distress to patients as well as putting lives at serious risk (file pic)
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.media won�t investigate medically-caused death numbers